Publications of Patrizio Lancellotti
Bookmark and Share    
Full Text
See detailDUSP3 Phosphatase Deficiency or Inhibition Limit Platelet Activation and Arterial Thrombosis
Musumeci, Lucia ULg; Kuijpers, Marijke; Gilio, Karen et al

in Circulation (in press)

Background A limitation of current antiplatelet therapies is their inability to separate thrombotic events from bleeding occurrences. Better understanding of the molecular mechanisms leading to platelet ... [more ▼]

Background A limitation of current antiplatelet therapies is their inability to separate thrombotic events from bleeding occurrences. Better understanding of the molecular mechanisms leading to platelet activation is of importance for the development of improved therapies. Recently, protein tyrosine phosphatases (PTPs) have emerged as critical regulators of platelet function. Methods and Results This is the first report implicating the dual-specificity phosphatase 3 (DUSP3) in platelet signaling and thrombosis. This phosphatase is highly expressed in human and mouse platelets. Platelets from DUSP3-deficient mice displayed a selective impairment of aggregation and granule secretion mediated through the collagen receptor glycoprotein VI (GPVI) and the C-type lectin-like receptor 2 (CLEC-2). DUSP3-deficient mice were more resistant to collagen- and epinephrine-induced thromboembolism, compared to wild-type mice, and showed severely impaired thrombus formation upon ferric chloride-induced carotid artery injury. Intriguingly, bleeding times were not altered in DUSP3-deficient mice. At the molecular level, DUSP3 deficiency impaired Syk tyrosine phosphorylation, subsequently reducing phosphorylation of PLCγ2 and calcium fluxes. To investigate DUSP3 function in human platelets, a novel small-molecule inhibitor of DUSP3 was developed. This compound specifically inhibited collagen and CLEC-2-induced human platelet aggregation, thereby phenocopying the effect of DUSP3 deficiency in murine cells. Conclusions DUSP3 plays a selective and essential role in collagen- and CLEC-2-mediated platelet activation and thrombus formation in vivo. Inhibition of DUSP3 may prove therapeutic for arterial thrombosis. This is the first time a PTP, implicated in platelet signaling, has been targeted with a small-molecule drug. [less ▲]

Detailed reference viewed: 14 (8 ULg)
See detailOral Abstract session: Stress echo in clinical practice: Friday 5 December 2014, 08:30-10:00Location: Agora.
Magne, J.; Donal, E.; Dulgheru, R. et al

Conference (2014, December)

Detailed reference viewed: 8 (0 ULg)
See detailPoster session 5: Friday 5 December 2014, 14:00-18:00Location: Poster area.
Henri, C.; DULGHERU, Raluca Elena ULg; Magne, J. et al

Poster (2014, December)

Detailed reference viewed: 2 (0 ULg)
See detailPoster session 6: Saturday 6 December 2014, 08:30-12:30Location: Poster area.
Henri, C.; DULGHERU, Raluca Elena ULg; Magne, J. et al

Poster (2014, December)

Detailed reference viewed: 6 (1 ULg)
See detailPoster session 4: Friday 5 December 2014, 08:30-12:30Location: Poster area.
Uejima, T.; Itatani, K.; Nakatani, S. et al

Poster (2014, December)

Detailed reference viewed: 2 (0 ULg)
See detailClub 35 Poster session 2: Thursday 4 December 2014, 08:30-18:00Location: Poster area.
Voilliot, D.; Magne, Jm; DULGHERU, Raluca Elena ULg et al

Poster (2014, December)

Detailed reference viewed: 5 (1 ULg)
See detailPoster session 3: Thursday 4 December 2014, 14:00-18:00Location: Poster area.
Gabriels, C.; LANCELLOTTI, Patrizio ULg; Van De Bruaene, A. et al

Poster (2014, December)

Detailed reference viewed: 10 (2 ULg)
See detailPoster session 1: Wednesday 3 December 2014, 09:00-16:00Location: Poster area.
Romano, G.; D'ancona, G.; Pilato, G. et al

Poster (2014, December)

Detailed reference viewed: 7 (4 ULg)
Full Text
See detailRecommandations européennes concernant la prise en charge de l'embolie pulmonaire.
MELISSOPOULOU, Maria ULg; ANCION, Arnaud ULg; LANCELLOTTI, Patrizio ULg

in Revue Medicale de Liege (2014), 69(11), 594-599

Detailed reference viewed: 15 (4 ULg)
Full Text
See detailLe médicament du mois Combinaison fixe périndopril-indapamide-amlodipine (Triplixam®) pour le traitement de l’hypertension artérielle
SCHEEN, André ULg; LANCELLOTTI, Patrizio ULg; KRZESINSKI, Jean-Marie ULg

in Revue Médicale de Liège (2014), 69(10), 565-570

Triplixam® is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension : perindopril, an ... [more ▼]

Triplixam® is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension : perindopril, an angiotensin converting enzyme inhibitor, indapamide, un diuretic whith thiazide-like effects but also specific properties, and amlodipine, a long-acting calcium antagonist of the dihydropyridine family. The potential synergic action allows better control of blood pressure with once daily administration, while limiting the incidence of adverse events. Various presentations with different dosages are available to facilitate individualized therapy. Warnings and precautions for use of every molecule should of course be respected. Such a fixed dose combination should contribute to limit clinical inertia and to improve therapeutic compliance. [less ▲]

Detailed reference viewed: 15 (0 ULg)
Full Text
See detail2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).
Elliott, Perry M.; Anastasakis, Aris; Borger, Michael A. et al

in European heart journal (2014), 35(39), 2733-79

Detailed reference viewed: 5 (0 ULg)
Full Text
See detailESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary.
Ryden, Lars; Grant, Peter J.; Anker, Stefan D. et al

in Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease (2014), 11(3), 133-73

Detailed reference viewed: 11 (0 ULg)
Full Text
See detailRecommandations européennes pour la prise en charge des cardiopathies congénitales complexes de l'adulte
MILTNER, Béatrice ULg; LANCELLOTTI, Patrizio ULg; SEGHAYE, Marie-Christine ULg

in Revue Médicale de Liège (2014), 69(1), 16-25

THe number of patients with Grown-Up Congenital Heart disease (GUCH) consulting adult cardiologists is steadily increasing. These patients have either a non-diagnosed congenital heart disease revealed at ... [more ▼]

THe number of patients with Grown-Up Congenital Heart disease (GUCH) consulting adult cardiologists is steadily increasing. These patients have either a non-diagnosed congenital heart disease revealed at adulthood, or a diagnosed congenital heart disease for which one or multiple interventions have possibly been performed during childhood. In this article, we summarize the recommendations of the European Society of Cardiology of 2010 for complex congenital heart disease. [less ▲]

Detailed reference viewed: 46 (4 ULg)
Full Text
See detail2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
Brignole, Michele; Auricchio, Angelo; Baron-Esquivias, Gonzalo et al

in Revista espanola de cardiologia (English ed.) (2014), 67(1), 58

Detailed reference viewed: 6 (0 ULg)
Full Text
See detailNormal reference ranges for echocardiography: do we really need more?
Lancellotti, Patrizio ULg

in European heart journal cardiovascular Imaging (2014), 15(3), 253-4

Detailed reference viewed: 15 (0 ULg)
Full Text
See detailRecommadantions européennes concernant la thérapie de resynchronisation cardiaque
ROBINET, Sébastien ULg; DELCOUR, Alexandre ULg; LANCELLOTTI, Patrizio ULg

in Revue Médicale de Liège (2014), 69(4), 180-187

La thérapie de resynchronisation cardiaque (CRT) est l'une des plus grandes avancées thérapeutiques depuis ces 25 dernières années dans le domaine de l'insuffisance cardiaque. Elle est applicable chez ... [more ▼]

La thérapie de resynchronisation cardiaque (CRT) est l'une des plus grandes avancées thérapeutiques depuis ces 25 dernières années dans le domaine de l'insuffisance cardiaque. Elle est applicable chez plus de 25-30% des patients décompensés cardiaques symptomatiques. Dans cet article, nous détaillons les recommandations de la Société Européenne de Cardiologie 2013 concernant la thérapie de resynchronisation cardiaque. [less ▲]

Detailed reference viewed: 20 (0 ULg)